Piroxicam pivalate

Drug Profile

Piroxicam pivalate

Alternative Names: CHF 1021; Ciclafast

Latest Information Update: 25 Mar 1999

Price : $50

At a glance

  • Originator Chiesi
  • Class Antirheumatics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Musculoskeletal disorders; Rheumatic disorders

Most Recent Events

  • 25 Mar 1999 Profile reviewed
  • 31 Jan 1997 A study in patients with rheumatic disorders has been added to the pharmacokinetics section
  • 14 Nov 1996 Launched for Musculoskeletal disorders in Italy (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top